Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 25;80(2):51-59.
doi: 10.4166/kjg.2022.096.

[Viral Hepatitis in Patients with Inflammatory Bowel Disease]

[Article in Korean]
Seung Hwan Shin  1 , Sang Hyoung Park  1
Affiliations
Review

[Viral Hepatitis in Patients with Inflammatory Bowel Disease]

[Article in Korean]
Seung Hwan Shin et al. Korean J Gastroenterol. .

Abstract
in English, Korean

There has been a rise in the incidence of inflammatory bowel disease (IBD) in developing countries, including South Korea. Consequently, the use of immunosuppressive agents such as immunomodulators or biologics has also increased. Due to immunosuppression, patients on these agents are at increased risk of various opportunistic infections during treatment, which may sometimes lead to serious adverse outcomes. Viral hepatitis, especially hepatitis B, is one of the infectious conditions that can be reactivated during immunosuppressive therapy, and adequate strategies for monitoring and prophylaxis are needed to prevent it. South Korea is one of the countries with intermediate endemicity for hepatitis A and B. Thus, taking adequate precautions against viral hepatitis could prevent new infections or reactivation of these conditions in patients with IBD on immunosuppressive therapy. In this review article, we have summarized the latest evidence on viral hepatitis in patients with IBD that would be of assistance in clinical practice.

There has been a rise in the incidence of inflammatory bowel disease (IBD) in developing countries, including South Korea. Consequently, the use of immunosuppressive agents such as immunomodulators or biologics has also increased. Due to immunosuppression, patients on these agents are at increased risk of various opportunistic infections during treatment, which may sometimes lead to serious adverse outcomes. Viral hepatitis, especially hepatitis B, is one of the infectious conditions that can be reactivated during immunosuppressive therapy, and adequate strategies for monitoring and prophylaxis are needed to prevent it. South Korea is one of the countries with intermediate endemicity for hepatitis A and B. Thus, taking adequate precautions against viral hepatitis could prevent new infections or reactivation of these conditions in patients with IBD on immunosuppressive therapy. In this review article, we have summarized the latest evidence on viral hepatitis in patients with IBD that would be of assistance in clinical practice.

Keywords: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis viruses; Inflammatory bowel diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None.

Figures

Fig. 1
Fig. 1
Algorithm for monitoring and prevention of hepatitis B reactivation. HBsAg, hepatitis B surface antigen; HBs, hepatitis B s antigen; HBc, hepatitis B core antigen; IgG, immunoglobulin G; HBV, hepatitis B virus; DNA, deoxyribonucleic acid; ALT, alanine aminotransferase.
See this image and copyright information in PMC

References

    1. GBD 2017 Inflammatory Bowel Disease Collaborators, author. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
    1. Kwak MS, Cha JM, Lee HH, et al. Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2019;34:1018–1026. doi: 10.1111/jgh.14542. - DOI - PubMed
    1. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019;13:1410–1417. doi: 10.1093/ecco-jcc/jjz081. - DOI - PubMed
    1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Sood A, Kaur K, Singh A, et al. Trends of inflammatory bowel disease at a tertiary care center in Northern India. Intest Res. 2021;19:282–290. doi: 10.5217/ir.2020.00010. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances